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Abstract: Somatostatin (SRIF) is a cyclic peptide widely distributed throughout the body with important
physiological effects (mostly inhibitory) on several organ systems. SRIF may act as a neurohormone,
neurotransmitter, neuromodulator or as a local factor, and exhibits potent antiproliferative activity. SRIF effects
have formed the basis for the clinical use of SRIF analogues in the treatment of endocrine tumours, acromegaly
and gastrointestinal disorders. Several data suggest that SRIF may also be a therapeutic target in a number of
different diseases.
The binding of SRIF to its five G-protein coupled receptors leads to modulation of multiple transduction
pathways, including adenylyl cyclase, guanylyl cyclase, phospholipase C, K+ and Ca2+ channels,
phospholipase A2, nitric oxide, Na+/H+ exchanger, protein phosphatases and MAP kinases. The diversity of
the transduction pathways reflects the pleiotropic actions of SRIF. However, our current understanding depicts
a rather complicated picture and conflicting results have also been reported. Data are mostly based on in vitro
experiments, and parallels with the real in vivo conditions are not so obvious. Due to the clinical relevance of
the SRIF system, the elucidation of the intracellular role of endogenous SRIF receptors may offer new
therapeutic perspectives. These will enable development of specific pharmacological signalling modulators
which can be incorporated into the therapeutic arsenal.
The present review represents a detailed and exhaustive summary which covers the latest advances in the
transduction pathways of SRIF receptors.
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1. INTRODUCTION gastrointestinal tract, the endocrine and exocrine pancreas,
several components of the immune system, and vessel walls
[4, 9]. Besides inhibiting GH secretion, SRIF has been
found to negatively regulate the secretion of many other
hormones including thyrotropin, corticotrophin releasing
hormone, adrenocorticotrophic hormone, insulin, glucagon,
secretin and vasoactive intestinal peptide hormone [4, 9].
SRIF also inhibits a variety of other physiological functions
such as gastrointestinal motility, gastric acid production,
pancreatic enzyme secretion, bile secretion and colonic fluid
secretion. In addition, SRIF exhibits potent antiproliferative
activity (cell-growth arrest and/or apoptosis) on both
cultured cells and tumours in experimental animals [3, 9].
Finally, it acts in the central nervous system with effects on
motor, sensory, cognitive and autonomic functions [10, 11].
In these different activities, SRIF acts as a neurohormone, a
neurotransmitter, a neuromodulator or as a local factor acting
via autocrine or paracrine mechanisms.
The Peptide Somatostatin
Somatostatin or SRIF (somatotropin release inhibiting
factor) is one of the longest known neuropeptides. It was first
discovered in 1968 in hypothalamic extracts as a low
molecular weight peptide which was shown to inhibit
growth hormone (GH) secretion from cultured anterior
pituitary [1]. In 1973, the same peptide, purified from bovine
pituitary, was also found to potently inhibit GH release and
was named somatostatin [2]. In mammals, SRIF is produced
from a single gene which encodes preprosomatostatin (116
amino acids). This is processed to prosomatostatin (96
amino acids) which is further cleaved to produce two
bioactive products: SRIF-14, which was the fourteen amino
acid peptide originally discovered, and SRIF-28, which has
an N-terminal extension of fourteen additional amino acids
[3].
Pathologically, SRIF has been linked to a number of
diseases including acromegaly, gastrointestinal disorders,
cancers, rheumatoid arthritis, diabetic retinopathy and
cystoid macular oedema [9, 12, 13]. Since it is expressed
and active in the central nervous system it is not surprising
that SRIF is also involved in various psychiatric or
neurological diseases including Alzheimer’s disease [14,
15], Huntington’s disease [16, 17], Parkinson’s disease
[18], HIV encephalitis [19], epilepsy [20], depression,
schizophrenia [21] and dementia [22].
SRIF is present in mammals and many non-mammalian
vertebrate classes including birds, amphibians, reptiles and
fish [4-8]. In general, it is involved in the regulation of the
functions of several organ systems including, for instance,
the central nervous system, the pituitary gland, the
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